Prevalence rates of mucopolysaccharidoses in Poland

被引:0
作者
Agnieszka Jurecka
Agnieszka Ługowska
Adam Golda
Barbara Czartoryska
Anna Tylki-Szymańska
机构
[1] University of Gdańsk,Department of Genetics
[2] Institute of Psychiatry and Neurology,Department of Cardiology
[3] Gliwice General Hospital,Department of Pediatrics, Nutrition and Metabolic Diseases
[4] The Children’s Memorial Health Institute,undefined
来源
Journal of Applied Genetics | 2015年 / 56卷
关键词
Mucopolysaccharidoses; Prevalence;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this study was to determine the prevalence rates of mucopolysaccharidoses in Poland and to compare them with other European countries. A retrospective epidemiological survey covering the period between 1970 and 2010 was implemented. Multiple ascertainment sources were used to identify affected patients. The overall prevalence of mucopolysaccharidoses in the Polish population was 1.81 per 100,000. Five different mucopolysaccharidoses were diagnosed in a total of 392 individuals. MPS III was the most frequent mucopolysaccharidosis, with a birth prevalence of 0.86 per 100,000 live births. A prevalence of approximately 0.22 cases per 100,000 births was obtained for MPS I. For MPS II, the prevalence was estimated as 0.45 cases per 100,000 births; for MPS IV A and B as 0.14 cases in 100,000 births; and that for MPS VI as 0.03 cases per 100,000 births. 1. The prevalence pattern of mucopolysaccharidosis in Poland is lower when compared to the prevalence reported for other European countries, such as the Netherlands, Czech Republic, or Germany, but similar to countries like Sweden and Denmark. 2. Different frequencies of the various forms of mucopolysaccharidosis were observed. 3. In the case of MPS VI, the incidence values for Poland were the lowest of all the studies previously published so far.
引用
收藏
页码:205 / 210
页数:5
相关论文
共 48 条
[1]  
Applegarth DA(2000)Incidence of inborn errors of metabolism in British Columbia, 1969–1996 Pediatrics 105 e10-1017
[2]  
Toone JR(2005)Cumulative incidence rates of the mucopolysaccharidoses in Germany J Inherit Metab Dis 28 1011-654
[3]  
Lowry RB(1997)Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism Eur J Pediatr 156 650-292
[4]  
Baehner F(1994)Human genetics. Jewish lysosomes Nature 368 291-598
[5]  
Schmiedeskamp C(2014)Treatment of lysosomal storage disorders: successes and challenges J Inherit Metab Dis 37 587-388
[6]  
Krummenauer F(2007)Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases J Appl Genet 48 383-699
[7]  
Coelho JC(2011)Mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome) with a predominantly cardiac phenotype Mol Genet Metab 104 695-243
[8]  
Wajner M(2012)Molecular analysis of mucopolysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia Mol Genet Metab 105 237-525
[9]  
Burin MG(2014)Mucopolysaccharidosis type VI in Russia, Kazakhstan, and Central and Eastern Europe Pediatr Int 56 520-222
[10]  
Diamond JM(1971)Relative frequency of the Hurler and Hunter syndromes N Engl J Med 284 221-390